{"url_path":"/sec/tvrd/8-k/2026-06-11/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 ****Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1346830/0001104659-26-072930-index.html","accession_number":"0001104659-26-072930","cik":"0001346830","ticker":"TVRD","issuer_name":"Tvardi Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1346830/0001104659-26-072930-index.html","primary_entity_key":"0001346830","primary_entity_name":"Tvardi Therapeutics, Inc."},"word_count":431,"has_tables":true,"body_markdown":"**Item 5.07****Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn June 9, 2026, Tvardi Therapeutics,\nInc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the\nCompany’s stockholders voted on the four proposals set forth below. A more detailed description of each proposal is set forth in\nthe Company’s Proxy Statement filed with the Securities and Exchange Commission on April 23, 2026.\n\n \n\n**Proposal 1 - Election of Directors**\n\n \n\nImran Alibhai, Ph.D., Cynthia\nSmith and Sujal Shah were each elected to serve as a Class II director of the Company’s Board of Directors until the 2029 Annual\nMeeting of Stockholders and until their successor is duly elected or until their earlier resignation or removal, by the following votes:\n\n \n\nNominee \nVotes For  \nVotes Withheld \n\nImran Alibhai, Ph.D. \n3,513,039  \n147,472 \n\nCynthia Smith \n3,392,877  \n267,634 \n\nSujal Shah \n3,507,652  \n152,859 \n\n \n\n**Broker Non-Votes:**\n2,975,429\n\n \n\n**Proposal 2 – Non-Binding, Advisory Vote\non Executive Compensation**\n\n \n\nThe stockholders approved,\non a non-binding advisory basis, the compensation of the Company’s named executive officers, by the following votes:\n\n \n\nVotes For \nVotes Against \nAbstentions \nBroker Non-Votes\n\n3,482,265 \n161,795 \n16,451 \n2,975,429\n\n \n\n**Proposal 3 - Advisory Vote on the Frequency\nof Solicitation of Advisory Stockholder Approval of Executive Compensation**\n\n \n\nThe stockholders indicated,\non an advisory basis, one year as the preferred frequency of stockholder advisory votes on the compensation of the Company’s named\nexecutive officers, by the following votes:\n\n \n\n1 Year \n2 Years \n3 Years \nAbstentions \nBroker Non-Votes\n\n3,453,729 \n9,343 \n15,435 \n182,004 \n2,975,429\n\n \n\nIn accordance with the recommendation\nof the Company’s Board of Directors and based on the results of the advisory vote reported above, the Company has determined\nthat it will hold future advisory votes on the compensation of the Company’s named executive officers on an annual basis until\nthe next required advisory vote on the frequency of stockholder advisory votes on the compensation of the Company’s named executive\nofficers.\n\n \n\n**Proposal 4 - Ratification of the Selection\nof Independent Registered Public Accounting Firm**\n\n \n\nThe stockholders ratified\nthe selection by the Audit Committee of the Board of Directors of the Company of Deloitte & Touche LLP as the Company’s independent\nregistered public accounting firm for its fiscal year ending December 31, 2026, by the following votes:\n\n \n\nVotes For \nVotes Against \nAbstentions \nBroker Non-Votes\n\n6,523,292 \n62,646 \n50,002 \n—\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned\nhereunto duly authorized.\n\n \n\n \nTVARDI THERAPEUTICS, INC.\n\n \n \n\nDate: June 11, 2026\nBy:\n/s/ Imran Alibhai\n\n \nName:\nImran Alibhai\n\n \nTitle:\nChief Executive Officer"}